Maddocks

Pharmacor wants to amend its defence in AstraZeneca's suit over the Australian drug maker's plans to launch a generic version of diabetes drug Forxiga so that it can argue a patent extension for the drug should not have been granted.

A Sydney council will argue its compulsory acquisition of two properties in Rouse Hill was part of a broader urban development public purpose, rather than the narrower purpose provided in its acquisition notice.

A tribunal has overturned a council decision which rejected National Storage’s proposal to build a two-storey storage facility and box shop in a rapidly expanding suburb in Melbourne’s south west. 

Property developer Castleway has succeeded in its challenge to a ruling limiting its payment entitlements under a development agreement with TPC Group.

A former director of two marketing companies linked to the failed Shield and First Guardian funds can leave Australia for 12 days, despite ASIC’s concerns he is a flight risk.

A director of med tech start-up Strongroom AI is claiming privilege against self-incrimination in a case by venture capital firm EVP seeking to recoup its $10.4 million investment.

A sacked property finance executive at CBA, who told an unnamed person in the workplace to “calm the f*** down”, has denied his conduct amounted to bullying, claiming swearing was common among his colleagues. 

Banksia Securities investors who agreed to drop their case alleging breaches linked to a scandal-ridden class action have been hit with costs, with a judge saying the case was “plainly” not for the benefit of all group members.

A tribunal has found Deloitte’s cost-benefit analysis on new energy efficiency standards is protected from disclosure under Freedom of Information laws because it contains trade secrets.

AstraZeneca has sued Pharmacor over its plans to list a generic version of blockbuster diabetes drug Forxiga on the PBS, but the drug maker will have to defend the validity of the patent, which was struck down by a UK court last year.